Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.
CITATION STYLE
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015, January 15). CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2014.00385
Mendeley helps you to discover research relevant for your work.